{'fraction_non_alphanumeric': 0.015910898965791568, 'fraction_numerical': 0.007159904534606206, 'mean_word_length': 5.197044334975369, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The best basic science paper on multiple sclerosis in 2012: Commentary

Clearly the greatest unmet need in the therapeutics of multiple sclerosis (MS) is a treatment which will protect axons from degenerating in the face of inflammatory attack and which will facilitate re-myelination. Our standard clinical approach is to use effective anti-inflammatory therapy to limit demyelination and axonal injury. This “outside–in” approach to the therapy of MS has partly been successful but we know that incomplete control of inflammation will eventually lead to axonal degeneration in axons deprived of myelin support. 2,3 Thus there is an overwhelming need to develop therapies which will both protect axons subject to inflammatory attack and promote axonal regeneration. Although there are a number of studies suggesting that drugs such as simvastatin4 and amiloride5 may be useful in progressive MS, we need more basic science knowledge to help us to devise therapies to address this problem. Repair appears to be more effective in the cortex; a recent paper from Bruce Trapp’s laboratory has demonstrated that in leucocortical MS plaques, which affected both white and grey matter equally, remyelination was more active in the grey matter part of the plaque.6